Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Belite BioFRA:D01 -2.99%19 Earnings Yield (Joel Greenblatt) % is -1.81% as of Jun. 2026. GuruFocus rates FRA:D01 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 1,344 Biotechnology companies, Belite Bio ranks better than 71.87% on this metric.
Belite Bio's Enterprise Value for the quarter that ended in Jun. 2026 was €5,396.45 Mil.
Belite Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-96.52 Mil. Belite Bio's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -1.81%.
The historical rank and industry rank for Belite Bio's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:D01'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2 Med: 0 Max: 0
Current: -2
FRA:D01's Earnings Yield (Joel Greenblatt) % is ranked better than 71.87% of 1344
companies
in the Biotechnology industry
Industry Median: -10.02
vs FRA:D01: -2.00
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Belite Bio's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Belite Bio (FRA:D01) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Belite Bio Earnings Yield (Joel Greenblatt) % Related Terms
Belite Bio Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Belite Bio's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Belite Bio's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belite Bio Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Belite Bio's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Belite Bio's Earnings Yield (Joel Greenblatt) % falls into.
Belite Bio Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Belite Bios Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Belite Bio's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-96.52 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -1.81% mean?
Belite Bio (FRA:D01) has a Earnings Yield (Joel Greenblatt) % of -1.81% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Belite Bio and its competitors. According to the industry distribution chart, Belite Bio ranks #378 out of 1344 companies in the Biotechnology industry, placing it in the top 28.1%.
Is Belite Bio's Earnings Yield (Joel Greenblatt) % too high?
Belite Bio's current Earnings Yield (Joel Greenblatt) % is -1.81%. Based on the distribution chart, Belite Bio ranks #378 out of 1344 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Belite Bio has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Earnings Yield (Joel Greenblatt) % compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, Belite Bio ranks #378 out of 1344 companies for Earnings Yield (Joel Greenblatt) %. This puts Belite Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Belite Bio and its competitors. Belite Bio's current Earnings Yield (Joel Greenblatt) % is -1.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (FRA:D01) has a current Earnings Yield (Joel Greenblatt) % of -1.81%. The current Earnings Yield (Joel Greenblatt) % is -1.81%. Belite Bio's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Belite Bio (FRA:D01), the current Earnings Yield (Joel Greenblatt) % is -1.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
19GF Score
Get the complete analysis for FRA:D01
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D01 has been successfully added to your 
